How much funding has ArmaGen Technologies raised?

ArmaGen Technologies has raised $17.0M in total funding, most recently a Series A round.

When was ArmaGen Technologies founded?

ArmaGen Technologies was founded in 2004.

Where is ArmaGen Technologies headquartered?

ArmaGen Technologies is headquartered in Calabasas, California, United States.

What industry is ArmaGen Technologies in?

ArmaGen Technologies operates in Biotech, Healthcare.

How many employees does ArmaGen Technologies have?

ArmaGen Technologies has 11-50 employees.

ArmaGen Technologies

Q: Who are ArmaGen Technologies's investors?

ArmaGen Technologies's investors include Boehringer Ingelheim Venture Fund, Shire plc, Takeda (JP), Mitsui & Co.

Calabasas, United States · Founded 2004 · $17.0M raised

Biotech

Healthcare

Headquarters: Calabasas, California
Employees: 11–50
Founded: 2004
Business Model: B2B

Total Funding: $17.0M
Last Round: $17.0M Series ANov 2012
Rounds: 1

About

ArmaGen Technologies (now ArmaGen, Inc.) was a clinical-stage biotechnology company focused on developing therapies for severe neurological disorders, specifically targeting the challenge of crossing the blood-brain barrier. Founded in 2004 by Dr. William M. Pardridge, the company pioneered receptor-mediated transcytosis technology, fusing therapeutics to antibodies that bind insulin or transferrin receptors to enable brain delivery. ArmaGen built a pipeline for lysosomal storage disorders including Hurler syndrome (MPS I), Hunter syndrome (MPS II), metachromatic leukodystrophy, and Sanfilippo syndromes. The company was acquired by JCR Pharmaceuticals in March 2020.

Summary

ArmaGen Technologies is a Biotech company based in Calabasas, United States, founded in 2004. It has raised $17.0M in total across 1 round, most recently a $17.0M Series A round in Nov 2012. Investors include Boehringer Ingelheim Venture Fund, Shire plc and Takeda (JP).